Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$7.75M$7.75Mderived+416.5% vs Q4 2021 Net Income-$27.64M-$27.64MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$29,079,000N/M Operating Cash Flowderived-$19,115,000N/M Free Cash Flowderived-$19,220,000N/M Margins · derivedOperating margin-375.1%+1150.1 pt vs Q4 2021
Net margin-356.4%+1162.8 pt vs Q4 2021
ended Dec 31, 2022 · filed Feb 23, 2023 · 54 d after period end